Erik Manting - 08 Jul 2021 Form 3 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Director
Signature: /s/ Thomas A. Fitzgerald, Attorney-in-Fact
Issuer symbol: RNAZ
Transactions as of: 08 Jul 2021
Net transactions value: $0
Form type: 3
Filing time: 08 Jul 2021, 21:53:12 UTC
Next filing: 22 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	RNAZ	Stock Option (Right to Buy)							08 Jul 2021	Common Stock	36,393	$3.91	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (December 1, 2020), provided that the Optionee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.

Content

Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (December 1, 2020), provided that the Optionee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.

Remarks:

Exhibit 24: Power of Attorney